Deutsch
Español
India
Italiano
Français
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Research
Benzinga Pro
Log In
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise
Contribute
Deutsch
Español
India
Italiano
Français
Sign in
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Intra-Cellular Therapies
(NASDAQ:ITCI)
Intraday
$72.13
0
[0.00%]
15 minutes delayed
Get Report
Watch
Perks
Buy
Compare Brokers
$72.13
0
[0.00%]
Last update: 4:20PM
Get Real Time Here
Get Report
Watch
Overview
News
Earnings
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest News for Intra-Cellular Therapies Stock (NASDAQ:ITCI)
Intra-Cellular Therapies Stock (NASDAQ: ITCI)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Wednesday, April 24, 2024
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $120 Price Target
Benzinga Newsdesk
-
2 days ago
Tuesday, April 23, 2024
Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $107
Benzinga Newsdesk
-
3 days ago
Monday, April 22, 2024
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90
Benzinga Newsdesk
-
4 days ago
The Analyst Verdict: Intra-Cellular Therapies In The Eyes Of 14 Experts
Benzinga Insights
-
4 days ago
Mizuho Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $96
Benzinga Newsdesk
-
4 days ago
Friday, April 19, 2024
How Is The Market Feeling About Intra-Cellular Therapies?
Benzinga Insights
-
Apr 19, 2024, 12:00PM
Thursday, April 18, 2024
Intra-Cellular Therapies shares are trading lower after the company priced a $500 million offering.
Benzinga Newsdesk
-
Apr 18, 2024, 3:42PM
Reported Earlier, Intra-Cellular Therapies Prices Public Offering Of 6,849,316 Common Shares At $73/Share
Benzinga Newsdesk
-
Apr 18, 2024, 3:42AM
Wednesday, April 17, 2024
Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Raises Price Target to $77
Benzinga Newsdesk
-
Apr 17, 2024, 11:31AM
B of A Securities Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $91
Benzinga Newsdesk
-
Apr 17, 2024, 7:59AM
Baird Maintains Outperform on Intra-Cellular Therapies, Raises Price Target to $103
Benzinga Newsdesk
-
Apr 17, 2024, 7:35AM
TD Cowen Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $90
Benzinga Newsdesk
-
Apr 17, 2024, 6:15AM
Abbott Laboratories, U.S. Bancorp And 3 Stocks To Watch Heading Into Wednesday
Avi Kapoor
-
Apr 17, 2024, 2:06AM
Tuesday, April 16, 2024
Intra-Cellular Therapies Announces $500M Proposed Public Offering Of Common Stock
Benzinga Newsdesk
-
Apr 16, 2024, 4:13PM
Intra-Cellular Therapies Inc Files For Mixed Shelf Offering, Size Not Disclosed
Benzinga Newsdesk
-
Apr 16, 2024, 4:06PM
Why Skillsoft Shares Are Trading Lower By Around 27%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Avi Kapoor
-
Apr 16, 2024, 2:17PM
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga Insights
-
Apr 16, 2024, 12:31PM
Intra-Cellular Stock Rallies On Successful Late-Stage Depression Treatment Study
Vandana Singh
-
Apr 16, 2024, 12:13PM
UnitedHealth Reports Upbeat Earnings, Joins Cullinan Oncology, Ericsson And Other Big Stocks Moving Higher On Tuesday
Avi Kapoor
-
Apr 16, 2024, 10:15AM
Intra-Cellular shares are trading higher after the company announced Lumateperone 42 mg once daily as adjunctive therapy to antidepressants met its primary endpoint.
Benzinga Newsdesk
-
Apr 16, 2024, 8:56AM
Market-Moving news for April 16th
Benzinga Newsdesk
-
Apr 16, 2024, 8:36AM
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga Insights
-
Apr 16, 2024, 8:07AM
Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $82 Price Target
Benzinga Newsdesk
-
Apr 16, 2024, 8:00AM
Trading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
Benzinga Newsdesk
-
Apr 16, 2024, 7:25AM
Intra-Cellular Reports Phase 3 Topline Results From Study 501 Evaluating Lumateperone As Adjunctive Therapy In Patients With Major Depressive Disorder; Lumateperone 42 Mg Met The Primary Endpoint
Benzinga Newsdesk
-
Apr 16, 2024, 7:03AM
Trading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
Benzinga Newsdesk
-
Apr 16, 2024, 6:55AM
Friday, April 05, 2024
Needham Reiterates Buy on Intra-Cellular Therapies, Maintains $82 Price Target
Benzinga Newsdesk
-
Apr 5, 2024, 5:15AM
Thursday, April 04, 2024
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Apr 4, 2024, 1:35PM
Wednesday, April 03, 2024
8 Analysts Assess Intra-Cellular Therapies: What You Need To Know
Benzinga Insights
-
Apr 3, 2024, 10:01AM
RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $86 Price Target
Benzinga Newsdesk
-
Apr 3, 2024, 8:52AM
Friday, February 23, 2024
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $101 Price Target
Benzinga Newsdesk
-
Feb 23, 2024, 12:13PM
RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $86 Price Target
Benzinga Newsdesk
-
Feb 23, 2024, 11:17AM
Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Lowers Price Target to $100
Benzinga Newsdesk
-
Feb 23, 2024, 9:51AM
Where Intra-Cellular Therapies Stands With Analysts
Benzinga Insights
-
Feb 23, 2024, 7:00AM
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $82
Benzinga Newsdesk
-
Feb 23, 2024, 6:46AM
Thursday, February 22, 2024
Intra-Cellular Therapies Sees 2024 CAPLYTA Net Product Sales $645M-$675M
Benzinga Newsdesk
-
Feb 22, 2024, 7:32AM
Intra-Cellular Therapies Q4 2023 GAAP EPS $(0.30) Beats $(0.45) Estimate, Total Revenues $132.10M Miss $135.67M Estimate
Benzinga Newsdesk
-
Feb 22, 2024, 7:31AM
Earnings Scheduled For February 22, 2024
Benzinga Insights
-
Feb 22, 2024, 5:27AM
Friday, February 16, 2024
Mizuho Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $82
Benzinga Newsdesk
-
Feb 16, 2024, 6:53PM
Wednesday, January 31, 2024
RBC Capital Reiterates Outperform on Intra-Cellular Therapies, Maintains $86 Price Target
Benzinga Newsdesk
-
Jan 31, 2024, 10:50AM
Thursday, January 18, 2024
Analyst Scoreboard: 8 Ratings For Intra-Cellular Therapies
Benzinga Insights
-
Jan 18, 2024, 9:00AM
Goldman Sachs Maintains Neutral on Intra-Cellular Therapies, Raises Price Target to $64
Benzinga Newsdesk
-
Jan 18, 2024, 8:50AM
Wednesday, January 03, 2024
Baird Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces Price Target of $83
Benzinga Newsdesk
-
Jan 3, 2024, 5:11AM
Tuesday, January 02, 2024
In-Depth Examination Of 6 Analyst Recommendations For Intra-Cellular Therapies
Benzinga Insights
-
Jan 2, 2024, 1:01PM
B of A Securities Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $82
Benzinga Newsdesk
-
Jan 2, 2024, 11:01AM
Thursday, December 14, 2023
10 Health Care Stocks Whale Activity In Today's Session
Benzinga Insights
-
Dec 14, 2023, 12:36PM
Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $101 Price Target
Benzinga Newsdesk
-
Dec 14, 2023, 12:26PM
Tuesday, December 12, 2023
Intra-Cellular Therapies Shares Higher; Traders Circulate Unconfirmed Report From M&A Blog Indicating Possible Takeover Interest
Benzinga Newsdesk
-
Dec 12, 2023, 11:58AM
Monday, December 11, 2023
Expert Ratings for Intra-Cellular Therapies
Benzinga Insights
-
Dec 11, 2023, 4:00PM
TD Cowen Initiates Coverage On Intra-Cellular Therapies with Outperform Rating, Announces Price Target of $75
Benzinga Newsdesk
-
Dec 11, 2023, 9:25AM
Show more
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch